GIP receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Faculty of Biotechnology Faculty of Chemistry Faculty of Philology Faculty of Physics and Astronomy Faculty of Mathematics and Computer Science Faculty of Biological Sciences Faculty of History and Pedagogy Faculty of Earth and Environmental Sciences Faculty of Social Sciences Faculty of Law, Administration and Economics
Structurally, the conjugated proteins are important in providing stability to cellular components and help intercellular communication which is why glycoproteins are commonly found in cell membranes and extracellular matrices.
With territories and frontiers that coincided largely with the ones of old Middle Ages East Francia and the 19th-century Napoleonic Confederation of the Rhine, the Federal Republic of Germany was founded on 23 May 1949 under the terms of the Bonn–Paris conventions, whereby it obtained "the full authority of a sovereign state" on 5 May 1955 (although "full sovereignty" was not obtained until the Two Plus Four Agreement in 1990). The former occupying Western troops remained on the ground, now as part of the North Atlantic Treaty Organization (NATO), which West Germany joined on 9 May 1955, promising to rearm itself soon. West Germany became a focus of the Cold War with its juxtaposition to East Germany, a member of the subsequently founded Warsaw Pact. The former capital, Berlin, had been divided into four sectors, with the Western Allies joining their sectors to form West Berlin, while the Soviets held East Berlin. West Berlin was completely surrounded by East German territory and had suffered a Soviet blockade in 1948–49, which was overcome by the Berlin airlift.
==== MeSH D12.776.467.374.480 – lymphokines ==== MeSH D12.776.467.374.480.350 – interferon type ii MeSH D12.776.467.374.480.372 – interleukin-2 MeSH D12.776.467.374.480.428 – leukocyte migration-inhibitory factors MeSH D12.776.467.374.480.438 – lymphotoxin MeSH D12.776.467.374.480.615 – macrophage-activating factors MeSH D12.776.467.374.480.615.350 – interferon type ii MeSH D12.776.467.374.480.625 – macrophage migration-inhibitory factors MeSH D12.776.467.374.480.640 – neuroleukin MeSH D12.776.467.374.480.700 – suppressor factors, immunologic MeSH D12.776.467.374.480.750 – transfer factor
=== Structure-activity relationships === In a virtual screen for novel agonists, a structure-activity relationship was determined from the most potent compounds ('hits') identified. These hits contained a pyrazolo[3,4-d]pyrimidine core (shown in figure 5), which is important for potency toward the 5-HT2C receptors. Compounds with maximum potency featured two substituents linked to the core structure. The first substituent is a piperazine ring, containing a small hydrophobic group; the second substituent is a phenyl part containing a halogen- and/or oxygen-containing side chain (electronegative groups), see derivatives 1 and 2 in figure 5. Addition of aromatic groups to the piperazine ring reduces potency (derivative 4 in figure 5) and the absence of the piperazine ring or substitution with other aliphatic- or cyclic groups reduces potency as well (derivatives 5 and 6 in figure 5).
Sources: en.wikipedia.org
In 1923–24 inventor Harry Grindell Matthews repeatedly claimed to have built a device that projected energy over long ranges and attempted to sell it to the War Office, but it was deemed to be fraudulent. His attempts spurred on many other inventors to contact the British military with claims of having perfected some form of the fabled electric or radio "death ray". Some turned out to be frauds and none turned out to be feasible. Around the same time, a series of stories suggested another radio weapon was being developed in Germany. The stories varied, with one common thread being a death ray, and another that used the signals to interfere with an engine's ignition system to cause the engine to stall. One commonly repeated story involved an English couple who were driving in the Black Forest on holiday and had their car fail in the countryside. They claimed they were approached by soldiers who told them to wait while they conducted a test, and were then able to start their engine without trouble when the test was complete. This was followed shortly thereafter by a story in a German newspaper with an image of a large radio antenna that had been installed on Feldberg in the same area. Although highly skeptical about claims of engine-stopping rays and death rays, the Air Ministry could not ignore them as they were theoretically possible. If such systems could be built, it might render bombers useless. If this were to happen, the night bomber deterrent might evaporate overnight, leaving the UK open to attack by Germany's ever-growing air fleet.
Germany has a social market economy with a highly skilled labour force, a low level of corruption, and a high level of innovation. It is the largest economy in Europe by nominal GDP, as well as the world's third-largest by nominal GDP and sixth-largest by PPP-adjusted GDP. Its PPP-adjusted GDP per capita amounted to 115% of the EU average in 2024. The country's service sector contributes approximately 72% of the total GDP, the industrial sector 27%—with Germany having the largest manufacturing output in Europe—and its agricultural sector 1%, as of 2023. The unemployment rate published by Eurostat amounts to 3.2% as of January 2020, which is the fourth-lowest in the EU. Germany is part of the European single market which represents more than 450 million consumers. In 2017, the country accounted for 28% of the eurozone economy according to the International Monetary Fund. Germany introduced the common EU currency, the euro, in 2002. Its monetary policy is set by the European Central Bank, which is based in Frankfurt, the country's largest financial centre. Germany is the world's third-largest exporter and third-largest importer, and it has the second-largest trade surplus after China. Its largest trading partners in 2025 were China, the United States and the Netherlands. Germany's main exports are vehicles, machinery, and chemical goods. The German automotive industry is among the most competitive and innovative in the world. It was the sixth-largest by production and largest by export value in 2023.
Cardiology: angioplasty, cardioversion, cardiac ablation, intra-aortic balloon pump Critical care medicine: mechanical ventilation Gastroenterology: endoscopy and ERCP Nephrology: dialysis Pulmonology: bronchoscopy Other tests are ordered, and patients are also referred to specialists for further evaluation. The effectiveness and efficiency of the specialist referral process is an area of potential improvement.
== S == SAII – Solvent-assisted ionization inlet SELDI – Surface-enhanced laser desorption/ionization SESI – Secondary electrospray ionization SHRIMP – Sensitive high-resolution ion microprobe SIFT – Selected ion flow tube SILAC – Stable isotope labelling by amino acids in cell culture SIM – Selected ion monitoring SIMS – Secondary ion mass spectrometry SIR – Selected ion recording SNMS – Secondary neutral mass spectrometry SRM – Selected reaction monitoring SWIFT – Stored waveform inverse Fourier transform SID – Surface-induced dissociation SIR – Surface-induced reaction SI – Surface ionization SORI – Sustained off-resonance irradiation
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.